Recent Quotes
My Watchlist
Indicators
Local Stocks
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Scholar Rock Holding Corp (NQ: SRRK )

29.98 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 30, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Scholar Rock Holding Corp

< Previous 1 2 3 4 5 6 7 8 9 Next >
Scholar Rock to Present New Clinical and Biomarker Data from the Phase 1 DRAGON Trial at the SITC 39th Annual Meeting
From Scholar Rock
Via Business Wire
Top 2 Health Care Stocks That May Fall Off A Cliff This Month
Via Benzinga
Scholar Rock Announces Closing of Full Exercise of Option to Purchase Additional Shares in Public Offering
From Scholar Rock
Via Business Wire
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Scholar Rock
Via Business Wire
How Is The Market Feeling About Scholar Rock Holding?
Via Benzinga
Here's Why Everybody's Talking About Scholar Rock Right Now
Successful clinical-trial results recently made Scholar Rock one of the stock market's top performers. 
Via The Motley Fool
Scholar Rock Announces Pricing of Upsized $300 Million Public Offering of Common Stock and Pre-Funded Warrants
From Scholar Rock
Via Business Wire
Nasdaq To Rally Around 13%? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
Scholar Rock Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
From Scholar Rock
Via Business Wire
Dow Tumbles Over 400 Points; Duckhorn Portfolio Shares Surge
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Crude Oil Gains Over 3%; Scholar Rock Shares Spike Higher
Via Benzinga
Exposures Fossil Fuels
Scholar Rock's Muscle Wasting Drug Excels In Pivotal Trial, Plans FDA Submission Next Year
Scholar Rock's Phase 3 SAPPHIRE trial for apitegromab in spinal muscular atrophy met its primary endpoint, showing statistically significant motor function improvements and favorable outcomes compared... 
Via Benzinga
Exposures Product Safety
Pfizer, Vista Outdoor, Duckhorn Portfolio And Other Big Stocks Moving Higher On Monday
Via Benzinga
US Stocks Open Lower; Dow Tumbles Over 150 Points
Via Benzinga
Topics Stocks
Exposures US Equities
Scholar Rock Catapults By Triple Digits On Final-Phase Win In Spinal Muscular Atrophy
The company is hoping to treat patients with spinal muscular atrophy, a muscle-wasting disease. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Scholar Rock Reports Apitegromab Meets Primary Endpoint in Phase 3 SAPPHIRE Study in Patients with Spinal Muscular Atrophy (SMA)
From Scholar Rock
Via Business Wire
Constellation Energy, Nike, Sinclair And Other Big Stocks Moving Higher On Friday
Via Benzinga
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Scholar Rock
Via Business Wire
Scholar Rock Completes Enrollment in Phase 2 EMBRAZE Proof-of-Concept Trial of Apitegromab in Obesity
From Scholar Rock
Via Business Wire
Scholar Rock Appoints Beth Shafer, Ph.D., to Chief Business Officer
From Scholar Rock
Via Business Wire
Scholar Rock to Participate in Upcoming Investor Conferences
From Scholar Rock
Via Business Wire
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Scholar Rock
Via Business Wire
SRRK Stock Earnings: Scholar Rock Holding Beats EPS for Q2 2024
SRRK stock results show that Scholar Rock Holding beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
Scholar Rock Reports Second Quarter 2024 Financial Results and Highlights Business Progress
From Scholar Rock
Via Business Wire
Scholar Rock to Host Conference Call to Discuss Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024
From Scholar Rock
Via Business Wire
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Scholar Rock
Via Business Wire
Scholar Rock Announces New SRK-439 Preclinical Data Showing Significant Lean Mass Preservation and Attenuation of Fat Mass Rebound Following GLP-1 Receptor Agonist Withdrawal
From Scholar Rock
Via Business Wire
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Scholar Rock
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.